| David R Trevino, MD | |
|
255 W Lancaster Ave, Mob Ii Suite 121, Paoli, PA 19301-1763 | |
| (610) 647-8885 | |
| (610) 640-3832 |
| Full Name | David R Trevino |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 50 Years |
| Location | 255 W Lancaster Ave, Paoli, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215918990 | NPI | - | NPPES |
| 110225028 | Other | PA | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD025295E (Pennsylvania) | Primary |
| 207RI0200X | Internal Medicine - Infectious Disease | MD025295E (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Main Line Health Home Care & Hospice - Home Health | Radnor, PA | Home health agency |
| Paoli Hospital | Paoli, PA | Hospital |
| Entity Name | Paoli Internal Medicine Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598724742 PECOS PAC ID: 5698764157 Enrollment ID: O20040510000874 |
News Archive
Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.
Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA's approval of four presentations of midazolam injection, USP, a general anesthetic. Sagent expects to launch midazolam, which will be offered in latex-free vials, in 2011. According to 2010 IMS data, the annual U.S. market for injectable midazolam approximated $52 million.
New research from the Masonic Cancer Center, University of Minnesota, and the University of Minnesota Center for Immunology has identified key proteins that influence immune response strategies, a finding that could influence new vaccination approaches.
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
The largest-ever study of the hazards of smoking and benefits of stopping for women in the UK has shown that female smokers lose at least ten years of lifespan, but that stopping before the age of 40, and preferably well before the age of 40, avoids more than 90% of the increased risk of dying caused by continuing to smoke, while stopping before the age of 30 avoids over 97% of it.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David R Trevino, MD 255 W Lancaster Ave, Mob Ii Suite 121, Paoli, PA 19301-1763 Ph: (610) 647-8885 | David R Trevino, MD 255 W Lancaster Ave, Mob Ii Suite 121, Paoli, PA 19301-1763 Ph: (610) 647-8885 |
News Archive
Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.
Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA's approval of four presentations of midazolam injection, USP, a general anesthetic. Sagent expects to launch midazolam, which will be offered in latex-free vials, in 2011. According to 2010 IMS data, the annual U.S. market for injectable midazolam approximated $52 million.
New research from the Masonic Cancer Center, University of Minnesota, and the University of Minnesota Center for Immunology has identified key proteins that influence immune response strategies, a finding that could influence new vaccination approaches.
Pfizer has announced that the U.S. Food and Drug Administration (FDA) has approved the use of its atypical antipsychotic Geodon(R) (ziprasidone HCI) for the treatment of acute bipolar mania including manic and mixed episodes.
The largest-ever study of the hazards of smoking and benefits of stopping for women in the UK has shown that female smokers lose at least ten years of lifespan, but that stopping before the age of 40, and preferably well before the age of 40, avoids more than 90% of the increased risk of dying caused by continuing to smoke, while stopping before the age of 30 avoids over 97% of it.
› Verified 9 days ago
Dr. Scott A. Olex, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 W Lancaster Ave, Paoli, PA 19301 Phone: 484-565-1510 Fax: 484-565-1513 | |
Matthew Levy, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Industrial Blvd Ste 200, Paoli, PA 19301 Phone: 610-647-2400 Fax: 610-647-3902 | |
Ronald Eric Krauser, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 11 Industrial Blvd., Suite 201, Paoli, PA 19301 Phone: 610-647-2398 Fax: 610-993-2867 | |
Dr. Elliot Mark Gerber, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 W Lancaster Ave, Medical Office Bldg Ii - Suite 328, Paoli, PA 19301 Phone: 610-647-2400 Fax: 610-647-3902 | |
Leo A Podolsky, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Industrial Blvd Ste 200, Paoli, PA 19301 Phone: 610-647-4260 Fax: 610-647-7430 | |
Emre Beken, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 W Lancaster Ave, Paoli, PA 19301 Phone: 484-565-1513 | |
Dr. Lisa R Kallenbach, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 2 Industrial Blvd, Ste 110, Paoli, PA 19301 Phone: 610-725-0650 Fax: 610-725-9583 |